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Introduction 
Antibiotics have been heralded as one of the greatest contributions to modern medicine. 
While antibiotics have been documented throughout many parts of the world, it was the 
discovery of penicillin in 1928 that marked the modern era of medicine.1 An antibiotic is a 
natural, semi-synthetic, or synthetic compound that interferes with the growth of, or results in the 
death of a microorganism, specifically bacteria.2 These medications are used to treat or prevent 
infection of humans or animals. With the advent of antibiotics, many infections that would cause 
significant morbidity and mortality were greatly reduced. The 1930s-1960s is regarded as the 
“golden age” of antibiotics, when most of the antibiotics still used today were created.2 Since 
then, there has been a dramatic slowing of antibiotic production. Several factors have contributed 
to this slowing, including their short-term nature which lowers their profit potential (compared to 
chronic disease medications), policies in place to reserve new antibiotics for use when current 
antibiotics fail, and increased regulations regarding antibiotic production. These factors have 
effectively dissuaded pharmaceutical companies from investing in novel antibiotics.3 For 
example, in 2004, only 1.6% of drugs in clinical development by the world’s fifteen largest 
pharmaceutical companies were antibiotics. Contrasted, antimicrobials account for more than 
30% of hospital pharmacy budgets in the US.3  
This is a large issue in medicine, as antibiotic resistance (ABR), or a pathogen’s ability to 
evolve and withstand the effects of antibiotics, increases worldwide.4,5 Several factors contribute 
to ABR including excessive use of antibiotics in humans and animals, poor sanitation, global 
migration, antibiotics sold over-the-counter, and release of nonmetabolized antibiotics into the 
environment through urine or feces.1 When bacteria become resistant to conventional treatments, 
more expensive, and toxigenic drugs are needed to combat them. Compared to susceptible 
bacterial infections, resistant infections are associated with an increase in morbidity, mortality 
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and prolonged hospital stay.4,5,6 The burden of ABR on society and their respective economies 
cannot be understated. In the US alone, antibiotic resistant hospital acquired infections cause 
99,000 deaths annually, a total of $20 billion in economic losses annually, and a loss of $35 
billion annually due to productivity loss.1  
It has been estimated that the burden of ABR in developing countries is even higher due 
to lack of resources.4,6 For example, in developed countries like the US, resistant bacterial 
infections may be treated with vancomycin or imipenem, which are more effective, but have 
increased cost and side effects. When contrasted in developing countries, many cannot afford 
these expensive treatments, preventing them from being readily available to the public.6  
Streptococcus Pneumoniae (S. Pneumoniae) is a gram-positive organism which is 
responsible for several bacterial infections in humans.7 90 serotypes exist to date and the 10 most 
common account for approximately 62% of invasive disease worldwide.7 S. Pneumoniae is the 
leading cause of pneumonia, meningitis, and bacteremia in adults and children. It is also the 
leading cause of otitis media (OM) in infants and children worldwide.7,8 Pneumonia is the most 
common cause of death in children younger than 5 years, with 1.6 million deaths occurring 
annually.8 People more likely to be infected with pneumococcal disease are children less than 2, 
adults 65 years or older, those with chronic conditions such as pulmonary disease, and those with 
immunosuppression.8 Pediatricians, geriatricians, and internists have an obligation to stay current 
on data regarding ABR S. Pneumoniae given their susceptible populations. 
S. Pneumoniae have become ABR to conventional treatments, including beta-lactams, 
macrolides, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMX), erythromycin and 
others.9 This is a trend worldwide and developing countries deserve special attention. Unlike 
developed countries like the US, there remain many barriers to effectively treating ABR S. 
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Pneumoniae infections such as cost of treatment, inaccessibility of healthcare and lack of 
infrastructure to analyze trends of ABR. This paper aims to identify some of the contributors to 
ABR S. Pneumoniae in developing countries with special attention to Latin America. In addition, 
this paper will explore some strategies that developed countries use to reduce or control ABR 
which developing countries can model. 
Background 
Antibiotic Use in Food and Animal Agriculture 
 One of the largest contributors to ABR is the use of antibiotics in agriculture. While S. 
Pneumoniae is human specific, and has no animal vector, the concept of antibiotic use in 
agriculture is still worth investigating due to its large impact on a global scale. Concomitant 
infection of S. Pneumoniae with ABR pathogens related to agriculture are possible and pose 
serious risk.  
Antibiotic use puts selective pressure on bacteria, eliminating susceptible bacteria while 
favoring the survival of resistant strains that have physiologic protective mechanisms against 
them. In agriculture, not only are antibiotics used for treatment of livestock, but also for 
proactive purposes. In metaphylaxis, if a farmer sees disease symptoms in one animal, they will 
treat all other animals with an antibiotic to prevent spread of that disease. Physiologic stress is 
commonly experienced by livestock due to their living conditions, which can cause 
immunosuppression. In order to combat this, farmers will often utilize prophylactic treatments, 
where a sub-therapeutic dose of an antibiotic is given to the immunocompromised animals to 
prevent infection.2 
Antibiotics have also been used in agriculture as a growth promoter leading to rapid 
growth in food animals and fish, while also contributing to an increase in ABR.2 This is a 
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frightening realization, as humans can become infected from ABR pathogens indirectly along the 
food chain through ingestion of food products or directly from colonized biological substances 
from animals such as blood, urine, feces, saliva and semen.2 Given the expansion of the global 
population, globalization of trade (especially food animals) and international travel, this is a 
problem that extends beyond borders. Every nation can be affected by this mounting issue. For 
this reason, it is imperative that local, regional, national and international regulations be put in 
place to monitor and regulate ABR. 
Developed countries, such as Denmark, Sweden, and the US have systems and programs 
in place to monitor antibiotic use in agriculture and ABR in food animals and products.2 
Developed countries such as these can analyze trends and implement national-level regulations 
to reduce the use of antibiotics in this sector. Denmark, for example, banned avoparcin in 1995, 
and in 2008 it was found that poultry production increased slightly, while reducing antibiotic 
consumption by 90%.2 These surveillance systems have proven to be effective in the 
management of antibiotic use in agriculture. 
In contrast to developed countries, most developing countries have no systems or 
programs that monitor antibiotic use or ABR in agriculture.2 In developing countries, there seems 
to be a large emphasis on antibiotic use for growth-promotion. A study by Eagar et. al. 
determined that two thirds of 1500 tons of antibiotics sold for animal use in South Africa over a 
three-year period were for growth-promotion purposes.2 It is also estimated that from 2010 to 
2030, up to a third of the global increase in antibiotic consumption in food animals will be 
attributed to lower-middle income countries.2 This is alarming as the majority of developing 
countries are major exporters of animals and their products. Brazil, for example, is the world’s 
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largest exporter of chicken meat.2 Any ABR bacteria seen in the chickens of that region, will 
surely reach across the globe.  
Unrestricted Access and Self-Medication 
One of the unique challenges that developing countries face regarding ABR is the 
unrestricted access to antibiotics. It is known that justified and controlled use of antibiotics 
contributes to ABR, however, widespread and unnecessary use exacerbates the situation. In 
many developing countries, the public have access to antibiotics over the counter without the 
need of a prescription. This problem is exacerbated by the fact that many of these antibiotics are 
acquired through unregulated supply chains.10,11 In general, the public acquires antibiotics from 
non-professional sources and their education surrounding when an antibiotic is indicated, how 
much to take, the side effects associated with them, and the duration of use is lacking.10,11 
To make factors worse, when antibiotic use is recommended, locals often prefer 
treatment from traditional healers who provide herbal supplements.11 This is especially true in 
rural areas, where many do not have adequate access to healthcare. While studying abroad in 
Costa Rica on July 7th, 2019, a rural resident of Longo Mai named Mercedes reported her 
preferences regarding treatment of illnesses, “I always prefer natural medicine over going to the 
doctor. This is because doctors give us chemicals which are bad for us. Also, it is at least 30 
minutes to the nearest clinic in Buenos Aires. I always choose natural medicine”. The 
composition and potency of these herbal remedies are unknown, therefore, the effects they exert 
on pathogens are also unknown. It is plausible these herbal remedies might produce 
antimicrobial effects, but, if given at sub-therapeutic doses, may confer ABR.11  
Self-medication practices have been shown to be excessive in Latin American 
countries.10 Several authors have attributed high prevalence of self-medication with antibiotics to 
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poor access to healthcare in several countries, such as Costa Rica, Nicaragua, Chile, Argentina, 
Brazil, and Colombia.10 Many developing countries, especially those in Latin America, seem to 
prefer unrestricted access to antibiotics in an effort to maintain reasonable access to medications. 
This is due to a recognition that if regulations were put in place, many would not have adequate 
access to receive the medications they may need.10 A study done in Guatemala by Ramay et. al. 
in 2015 revealed the top four antibiotics used in self-medication were: amoxicillin, tetracycline, 
TMP-SMX, and erythromycin. (Table 1)10 These are some of the first line medications used in 
the treatment of S. Pneumoniae infections, which is problematic. 
ABR Serotypes and Pneumococcal Conjugate Vaccine 
 Although all pneumococcal infections can be treated with antibiotics, the available 
choices are limited for some strains. While antibiotics are used as a reactive approach to 
treatment of bacterial infections, vaccinations are a proactive approach to prevent bacterial 
infections from happening in the first place. Pneumococcal conjugate vaccines (PCVs) are 
effective against invasive pneumococcal disease (IPD) and have a significant effect directly on 
those who acquire them as well as indirectly.8 
In the US, multi-drug resistant strains of S. Pneumoniae were first isolated in children 
and are predominantly associated with pediatric serotypes (6A, 6B, 9V, 14, 19A, 19F and 23F).8 
Because of the pneumococcal vaccine, less multi-drug resistant strains of S. Pneumoniae were 
reported in the US within 14 years of its introduction. A shift of multi-drug resistant strains has 
now been reported in serotypes 15A, 15B, 15C, 6C, 23A, and 35B. Multi-resistant serotype 19A 
isolates are still reported with the highest resistance to beta-lactams, macrolides, tetracycline, co-
trimoxazole and lincosamides.8 Just 4 years after the introduction of the pneumococcal conjugate 
vaccine-7 (PCV-7) in 2000, which covers the most common ABR serotypes (4, 6B, 9V, 14, 18C, 
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19F, and 23F) the US witnessed a decrease in penicillin-resistant S. Pneumoniae infections from 
6.3 to 2.7 per 100,000, and multi-drug resistant S. Pneumoniae infections (4.1 to 1.7 cases per 
100,000). (Figure 1)8 Vaccine-type resistant S. Pneumoniae disease decreased by 87% following 
the introduction of the PCV-7 in the US.8 Similar findings can be seen throughout the world. For 
example, after the introduction of the PCV-10 in Brazil, there was a decrease in penicillin and 
ceftriaxone resistant S. Pneumoniae infections. 
 In Latin America, most ABR S. Pneumoniae infections are caused by serotypes 6A, 6B, 
9V, 14, 19A, 19F, and 23F. Serotype 23F, a clonal serotype from Spain, which is resistant to 
penicillin, chloramphenicol, tetracycline and erythromycin, has had a large impact on this 
region.6,9 These serotypes reflect similar trends in developed countries such as the US. In Latin 
America, countries with the highest percentage of penicillin-resistant isolates are Puerto Rico 
(35%) and Peru (27%). The highest median percentage of S. Pneumoniae isolates with high- 
level resistance was found in children less than 5 years of age. Mexico reported the highest rate 
of penicillin-resistant pneumococcal isolates (22%) and 47% overall ABR. Argentina reported 
the highest penicillin resistant OM isolates (80%). It is worth noting that OM represents 79% of 
all infections caused by S. Pneumoniae in Latin America and the Caribbean. Consequently, this 
results in most of the consumption of antibiotics in the region.9 Providing PCVs in this region is 
therefore of utmost importance. 
Unfortunately, many developing countries, and Latin American countries specifically, do 
not have adequate access to these vaccines. For example, the PCV-7 became available to Costa 
Rica in 2004. While this is beneficial for the country, it was estimated that only 10-15% of 
children in Costa Rica had access to this vaccine.12 This was attributed to economic limitations, 
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leaving the vaccine available only to children who had private insurance. Proper access to PCVs 
in developing countries would decrease the burden of pneumococcal disease as well as ABR. 
Clinical Practice Guidelines, Surveillance and Improper Prescribing Practices 
In modern medicine, the use of empirical treatment guidelines for specific infections is an 
important part of quality healthcare. The same is true for S. Pneumoniae infections. In developed 
countries such as the US, societies like the Infectious Disease Society of America and the 
American Thoracic Society (IDSA/ATS) have provided specific treatment guidelines for 
practitioners to use in the treatment of pneumonia infections.14 These guidelines are generated 
based upon current data highlighting effective antimicrobial agents. In the US, pneumococcal 
disease data is constantly monitored using the population-based survey system called Active 
Bacterial Core Surveillance Program (ABC).8 The US then uses this data to update and educate 
medical providers on trends of ABR pneumococcal disease and provide appropriate treatment 
guidelines.  
According to the IDSA/ATS, recommended treatment guidelines for pneumonia are: 
macrolide or doxycycline in a previously healthy person with no risk factors for ABR S. 
Pneumoniae infection, a respiratory fluoroquinolone or beta-lactam plus a macrolide if the 
patient has comorbidities such as heart disease or been previously exposed to antibiotics in the 
previous 3 months, and use of the previous agents mentioned if local macrolide-resistant S. 
Pneumoniae infections are prevalent (>25%).8 Guidelines, therefore, depend on adequate 
surveillance in order to be effective. 
Many Latin American countries do not have adequate surveillance systems in place to 
make proper treatment guidelines for their area. Because of this, much of the rudimentary data in 
these countries are based solely on point-prevalence assessments or case studies.6 For this 
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reason, the IDSA/ATS guidelines for pneumococcal disease have been used by Latin American 
countries as a reference for treatment.14 While this is a valuable resource and much of the trends 
of pneumococcal infections and ABR patterns in the US have been similar in Latin American 
countries, proper prescribing practices are necessary on the part of medical providers. 
A study done in 2015 by Gattarello et. al. demonstrated that when physicians from Latin 
American countries were given fictional patient cases with community-acquired pneumonia 
(CAP) and nosocomial pneumonia, 31% of CAP cases and only 3% of nosocomial pneumonia 
cases were considered adequate treatments following the IDSA/ATS guidelines. (Table 2)14 This 
reflects the need for not only proper surveillance and guidelines in Latin American countries, but 
for adequate and ongoing education for medical providers. Without continuing education, 
medical providers will continue to prescribe improper treatments for S. Pneumoniae infections, 
further contributing to burden of disease and ABR. 
Methods 
  This was a literature review conducted using PubMed. A search was done using 
keywords such as “antibiotic resistance, Streptococcus Pneumoniae, developing countries, Latin 
America, Costa Rica and clinical guidelines”. Initially, 27 articles were collected and filtered 
based upon relevance to the topic, date of publication and redundancy of information to other 
articles used during June and July of 2019. Fourteen articles were used in this literature review. 
Some government websites were utilized for general background information on healthcare. A 
brief interview was conducted with Mercedes, a resident of a rural community called Longo Mai 
in Costa Rica, regarding her opinion on healthcare and antibiotics. Another interview was 
conducted with Dr. Jose Alejandro Madrigal Lobo, a member of the Costa Rican Doctor’s 
Association regarding the healthcare system in Costa Rica. 
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Discussion 
 While modern medicine has made large impacts on global health, finances are a 
consistent barrier to adequate access to healthcare. Specifically, the advent of antibiotics 
introduced new challenges to the medical community. Antibiotics are a mainstay to the treatment 
of infectious disease but have contributed to global ABR pathogens. As previously stated, ABR 
infections increase morbidity and mortality worldwide, require constant surveillance and 
necessitate novel treatments. Countries in Latin America are still considered developing and just 
don’t have the ability to combat ABR like developed countries. While barriers exist, small policy 
changes could have positive impacts on these countries. 
 Winning the battle with ABR infections such as S. Pneumoniae require national and 
international efforts. Surveillance systems that monitor ABR patterns from major regions 
throughout the country will determine proper therapeutic guidelines. While many Latin 
American countries do not have this in place, it is a goal that should be worked on to improve 
outcomes regarding ABR infections. Placing surveillance programs at large tertiary hospitals 
throughout Latin American countries where proper microbiological testing is available could 
help the situation. When patients with severe infections go to the hospital, often they will receive 
cultures and other laboratory tests to determine the nature of the disease. Implementing a 
recording program in these countries could help better understand local and regional patterns of 
ABR. 
 While many medical providers have understanding regarding treatments for common 
infections, it is apparent that many do not stay current with therapeutic guidelines, especially 
more complex cases. Continuing education for medical providers is imperative so they can make 
the best recommendation for their patients. International cooperation from medical providers in 
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developed, high-income countries may be a feasible way to ensure medical providers in 
developing countries like Latin America stay current on treatment guidelines. 
 Antibiotic use in agriculture is a large issue in developing countries that has major 
implications across the world. As previously stated, S. Pneumoniae is a human-only pathogen 
and doesn’t reside in animals, however, due to the global implications of antibiotic use in 
agriculture, and the risk of multiple infections, it is important to address. Developing countries 
could benefit from the replication of models used in developed countries. While there are 
barriers to implementing complex infrastructure involving cost and human resources, it is a goal 
that is imperative to achieve. One policy that could be implemented in developing countries is 
restricting access of antibiotics to farmers. Currently, most developing countries do not require 
veterinarian oversight to access antibiotics. Adding nation-wide regulations that strictly prohibit 
access to antibiotics without veterinary oversight in developing countries like Latin America 
could be a step towards effective management of this issue. Also, providing farmers with 
education surrounding ABR is important. Countries should also implement policies that restrict 
the use of antibiotics as growth promoters, like many developed nations. 
The use of over-the-counter antibiotics for human consumption is another issue that 
needs to be addressed in developing countries. Uneducated and unrestricted use of antibiotics can 
contribute to ABR in S. Pneumoniae infections. The absence of healthcare professionals in 
pharmacies and lack of regulations for antibiotic prescriptions is a contributing factor. If the role 
of the pharmacist became more integral to the acquisition of antibiotics, patients would likely 
become more educated surrounding them.10 In order to do this, developing countries need to 
develop laws that regulate the dispensing of medications. Like many developed countries that 
require prescriptions for acquisition of antibiotics, a stricter policy along with the integration of 
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pharmacists would improve safety, rational use, and affordability of antibiotics.10,11 One might 
question how policies introducing more regulations would be cost effective. Up front cost would 
surely rise, but the benefits it would impose by decreasing overall ABR infections, the need for 
more invasive and costly treatments, and hospitalizations would make up for upfront costs. 
 Vaccine programs are important for protection of the population and prevention of ABR 
pneumococcal infections. While implementing PCVs in developing countries like Latin America 
may be difficult due to financial constraints, it is still important to continue to advocate for them. 
Pneumococcal disease represents a large majority of infectious disease across the world. With 
the introduction of the PCV-7 vaccine in the United States, pneumococcal infections dropped 
significantly. Much of the cost required to treat those who become infected is therefore abated. 
Research on cost-effective implementation of vaccines in developing countries will be more 
productive than treatment of pneumococcal infections themselves. 
Conclusion 
 ABR is a global issue and persists despite advanced efforts to control it. This is 
compounded by the fact that there has been little development of new antibiotics to combat this. 
ABR infections pose significant morbidity and mortality worldwide as conventional antibiotics 
have become less effective. This is especially true for S. Pneumoniae, which as previously stated 
causes most invasive disease worldwide. The problem of ABR S. Pneumoniae becomes 
exponential in developing countries where they lack the proper resources to implement 
surveillance infrastructure to track ABR, development of proper guidelines based upon local 
data, education for medical providers on current empiric treatment guidelines, access to 
vaccinations and more costly treatments. These problems are further exacerbated by the high 
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prevalence of self-medication of antibiotics which are frequently acquired over-the-counter, 
without education regarding these medications.  
ABR is an issue that spans across borders and global efforts should be implemented to 
improve these disparities for developing countries such as Latin America. Joint global funding, 
research, and education guidelines could be implemented in developing countries to improve 
outcomes, with a priority to common infectious diseases that cause significant morbidity and 
mortality, such as S. Pneumoniae. Understanding the disparities that developing countries face 
regarding ABR is an instrumental part to the creation of a solution. Now that many disparities 
are understood, implementation of nation-wide policies aimed at reducing ABR needs to be 
investigated. It is easy to say such policies need to be created but the actual implementation of 
them is far more challenging. Future research should focus on feasible ways to implement the 
strategies outlined in this paper to improve healthcare in developing countries. Even small 
changes in policy will help decrease ABR and improve global health. 
 
  
  
 
 
 
 
 
 
 
 
 
16 
 
References 
1. Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global 
crisis. Infect Drug Resist. 2018;11:1645–1658. Published 2018 Oct 10. 
doi:10.2147/IDR.S173867 
 
2. Founou LL, Founou RC, Essack SY. Antibiotic Resistance in the Food Chain: A 
Developing Country-Perspective. Front Microbiol. 2016;7:1881. Published 2016 Nov 23. 
doi:10.3389/fmicb.2016.01881 
 
3. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin 
Chem. 2014;6:25–64. Published 2014 Aug 28. doi:10.4137/PMC.S14459 
 
4. Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic 
convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S 
A. 2018;115(15):E3463–E3470. doi:10.1073/pnas.1717295115 
 
5. Davey P,Marwick CA, ScottCL, Charani E,McNeilK, Brown E,Gould IM, Ramsay CR, 
Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. 
Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No.: CD003543.DOI: 
10.1002/14651858.CD003543.pub4. 
 
6. Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing 
countries. part I: Recent trends and current status. The Lancet Infectious Diseases. 
2005;5(8):481493.http://www.sciencedirect.com/science/article/pii/S1473309905701894. 
doi: 10.1016/S1473-3099(05)70189-4. 
 
7. The Pink Book, Chapter 17: Pneumococcal Disease. CDC.org. 
https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html#. Published 2015. Updated 
May 16, 2018. Accessed July 20th, 2019.  
 
8. Kim L, McGee L, Tomczyk S, Beall B. Biological and Epidemiological Features of 
Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: 
a United States Perspective. Clin Microbiol Rev. 2016;29(3):525–552. 
doi:10.1128/CMR.00058-15 
 
9. M. Teresa Valenzuela, Ciro de Quadros. Antibiotic resistance in Latin America: A cause 
for alarm. Vaccine, Volume 27, Supplement 3, 2009, Pages C25-C28, ISSN 0264-410X, 
https://doi.org/10.1016/j.vaccine.2009.06.005.(http://www.sciencedirect.com/science/arti
cle/pii/S0264410X09008536) 
 
10. Ramay BM, Lambour P, Cerón A. Comparing antibiotic self-medication in two socio-
economic groups in Guatemala City: a descriptive cross-sectional study. BMC Pharmacol 
Toxicol. 2015;16:11. Published 2015 Apr 27. doi:10.1186/s40360-015-0011-3 
 
 
17 
 
11. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in 
developing countries: causes and control strategies. Antimicrob Resist Infect Control. 
2017;6:47. Published 2017 May 15. doi:10.1186/s13756-017-0208-x 
 
12. Arguedas A, Dagan R, Guevara S, et al. Middle Ear Fluid Streptococcus pneumoniae 
Serotype Distribution in Costa Rican Children with Otitis Media. The Pediatric Infectious 
Disease Journal. 2005;24(7):631-634. doi:10.1097/01.inf.0000168748.92510.45. 
 
13. GBD 2015 Healthcare Access and Quality Collaborators. Electronic address: 
cjlm@uw.edu; GBD 2015 Healthcare Access and Quality Collaborators. Healthcare 
Access and Quality Index based on mortality from causes amenable to personal health 
care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden 
of Disease Study 2015. Lancet. 2017;390(10091):231–266. doi:10.1016/S0140-
6736(17)30818-8 
 
14. Gattarello S, Ramírez S, Almarales JR, et al. Causes of non-adherence to therapeutic 
guidelines in severe community-acquired pneumonia. Rev Bras Ter Intensiva. 
2015;27(1):44–50. doi:10.5935/0103-507X.20150008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
Appendices 
 
Table 1. Reported most common antibiotic purchases when self-medicating.10 
 
 
Table 2. Antibiotic prescription, dose and duration in the case of CAP.14 
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Figure 1. ABCs IPD rates in 1999, 2009 (9 years after PCV7 introduction), and 2013 (3 years after PCV13 
introduction).8 
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